Evolent Health (EVH)

Overall impact
C (53)

Commentary

Evolent Health is an average overall performer. With a 'C' rating of 53.2 for overall impact (48th percentile compared to all companies), Evolent Health ranks 74th out of 96 industry peers, behind Suvoda, Gainwell Technologies, Maximus and 70 others, and ahead of Progyny, Castle Biosciences, Pro Medicus and 19 others. On top material causes for Evolent Health's industry (Healthcare Software & Services), Evolent Health performs poorly in Technology Innovation (38.1 score), Access to Affordable Healthcare (37.6) and Fair Labor Practices (37.4). Evolent Health did not receive an 'A' rating on any cause.
Impact
Cause EVH
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
4,200
Sector
Health Care
Industry
Health Care Providers & Services
Sub-industry
Health Care Services
SASB industry
Software & IT Services
Headquarters
Va, United States
Share classes
EVH
Description
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers an integrated platform for health plan administration and value-based business infrastructure. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management. Additionally, Evolent Health offers Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management and Machinify Auth, a software platform that leverages advances in artificial intelligence. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Material causes
Ethos considers the following causes material for Evolent Health, based on its industry sub-industry Health Care Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.